RGC
NBIX icon

Roberts, Glore & Co’s Neurocrine Biosciences NBIX Stock Holding History

Roberts, Glore & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,492
Closed -$212K – 231
2025
Q4 		$212K Hold
1,492
– – 0.06% 211
2025
Q3 		$209K Buy
+1,492
New +$202K 0.06% 210
2025
Q1 		– Sell
-1,492
Closed -$204K – 209
2024
Q4 		$204K Buy
+1,492
New +$185K 0.06% 203
2024
Q3 		– Sell
-1,492
Closed -$205K – 212
2024
Q2 		$205K Hold
1,492
– – 0.06% 197
2024
Q1 		$206K Buy
+1,492
New +$204K 0.06% 201

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Roberts, Glore & Co's NBIX Position: Q1 2026 in Review

Roberts, Glore & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 1,492 shares — an estimated $212K sold.

Roberts, Glore & Co first reported a position in NBIX in Q1 2024 and held it in 5 quarters. The position peaked at $212K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Roberts, Glore & Co reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Roberts, Glore & Co sold 1,492 Neurocrine Biosciences shares in Q1 2026, an estimated $212K.
  • Roberts, Glore & Co first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 5 quarters.
  • Roberts, Glore & Co's Neurocrine Biosciences position peaked at $212K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.